COX-2 controversy: where are we and where do we go from here?

Author： Khanna Dinesh  

Publisher： VSP

ISSN： 1568-5608

Source： Inflammopharmacology, Vol.13, Iss.4, 2005-09, pp. : 395-402

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Acetaminophen safety and hepatotoxicity – where do we go from here?

By Amar Patrick J   Schiff Eugene R  

Expert Opinion on Drug Safety, Vol. 6, Iss. 4, 2007-07 ,pp. : 341-355

Informa Healthcare

Access to resources Recommend Favorite

Where Do We Go from Here? The Importance of Initial Values

By Mehta M.A.  

Neuropsychopharmacology, Vol. 27, Iss. 5, 2002-11 ,pp. : 879-880

Elsevier

Access to resources Recommend Favorite

Contingency Management for Smoking Cessation: Where Do We Go from Here?

By  

Current Drug Abuse Reviews, Vol. 1, Iss. 3, 2008-11 ,pp. : 340-349

Bentham Science Publishers

Access to resources Recommend Favorite

Phosphodiesterase 4 Inhibitors and the Treatment of Asthma: Where Are We Now and Where Do We Go from Here?

By Giembycz M.A.  

Drugs, Vol. 59, Iss. 2, 2000-02 ,pp. : 193-212

Adis International

Access to resources Recommend Favorite

Theoretical Arguments for the Discounting of Health Consequences: Where Do We Go from Here?

By Lazaro A.  

PharmacoEconomics, Vol. 20, Iss. 14, 2002-01 ,pp. : 943-961

Adis International

Access to resources Recommend Favorite